Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free DRMAW Stock Alerts

Dermata Therapeutics (DRMAW) Competitors

Dermata Therapeutics logo
$0.01 +0.00 (+8.04%)
As of 03:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DRMAW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Dermata Therapeutics compare to Ainos?

Dermata Therapeutics (NASDAQ:DRMAW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Ainos$124.16KN/AN/AN/AN/A

In the previous week, Dermata Therapeutics had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Dermata Therapeutics' score of 0.93 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Positive
Ainos Very Positive

Summary

Ainos beats Dermata Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Dermata Therapeutics compare to Alvotech?

Dermata Therapeutics (NASDAQ:DRMAW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

In the previous week, Dermata Therapeutics and Dermata Therapeutics both had 2 articles in the media. Alvotech's average media sentiment score of 1.44 beat Dermata Therapeutics' score of 0.93 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Dermata Therapeutics Positive
Alvotech Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Dermata Therapeutics on 2 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Aravive. Dermata Therapeutics' average media sentiment score of 0.93 beat Aravive's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Dermata Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Summary

Aravive and Dermata Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does Dermata Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Dermata Therapeutics (NASDAQ:DRMAW) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Dermata Therapeutics had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for Dermata Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Dermata Therapeutics' average media sentiment score of 0.93 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Dermata Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

Summary

Dermata Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Avidity Biosciences?

Dermata Therapeutics (NASDAQ:DRMAW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Dermata Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Dermata Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Avidity Biosciences -3,650.39%-44.92%-39.57%

Avidity Biosciences has a consensus price target of $69.42, indicating a potential upside of 423.14%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Dermata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32

Dermata Therapeutics has higher earnings, but lower revenue than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A

In the previous week, Avidity Biosciences had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for Dermata Therapeutics. Avidity Biosciences' average media sentiment score of 0.94 beat Dermata Therapeutics' score of 0.93 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dermata Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Avidity Biosciences beats Dermata Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRMAW vs. The Competition

Export
MetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$458.97M$6.29B$12.46B
Dividend YieldN/A3.86%2.79%5.30%
P/E RatioN/A3.8120.8725.58
Price / SalesN/A7,812.85521.6363.56
Price / CashN/A13.1342.9455.34
Price / BookN/A83.889.866.70
Net IncomeN/A-$96.07M$3.55B$333.77M
7 Day PerformanceN/A0.71%-0.32%0.45%
1 Month PerformanceN/A0.60%1.34%4.06%
1 Year PerformanceN/A70.45%41.03%36.21%

Dermata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRMAW
Dermata Therapeutics
N/A$0.01
+22.3%		N/A-44.8%$0.00N/AN/A8
AIMDW
Ainos
N/A$0.09
-17.7%		N/A-21.3%$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.28
+29.4%		N/A-86.0%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DRMAW) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel
Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...
InvestorPlace | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel